Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Diabetic Gastroparesis Treatment Market Expected To Reach $5.46 Billion By 2030 At 6.3% CAGR
The market for diabetic gastroparesis treatments has experienced significant expansion recently, projected to increase from $4.05 billion in 2025 to $4.28 billion in 2026, reflecting a compound annual growth rate of 5.7%. This historical growth trajectory is underscored by several key factors, including the increasing prevalence of diabetes-related complications, a past scarcity of therapeutic choices, heightened diagnostic capabilities, a strong dependence on pharmaceutical interventions, and the expanding field of specialized gastroenterological care.
Anticipated to experience robust expansion in the coming years, the market for diabetic gastroparesis treatments is projected to reach $5.47 billion by 2030, demonstrating a compound annual growth rate of 6.3%. This projected growth during the forecast period is fueled by advancements in novel prokinetic agents, heightened public and medical awareness of the condition, the proliferation of specialized treatment centers, a persistent need for sustained symptom relief, and ongoing innovations in gastric electrical stimulation technologies. Key developments expected to shape the market include a greater reliance on prokinetic drug therapies, intensified attention on managing symptoms rather than solely pursuing a cure, the growing application of combined pharmacological approaches, increased uptake of interventions requiring minimal invasiveness, and a more pronounced focus on managing the condition through diet and lifestyle modifications.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12580&type=smp
Diabetic Gastroparesis Treatment Market Demand Drivers: What Is Fueling Industry Growth?
The escalating incidence of diabetes is anticipated to serve as a significant catalyst for the expansion of the diabetic gastroparesis treatment market in the coming years. Diabetes prevalence, understood as the quantifiable share or percentage of individuals diagnosed with this condition within a defined timeframe, directly influences the demand for treatments aimed at mitigating the symptoms and subsequent issues arising from diabetic gastroparesis, a frequent diabetic complication. To illustrate, by April 2025, the International Diabetes Federation indicated a global population of approximately 589 million adults aged 20–79 living with diabetes, with projections suggesting this figure could escalate to 853 million by 2050. Consequently, the growing widespread occurrence of diabetes is a primary factor stimulating the diabetic gastroparesis treatment market.
Advancements in surgical interventions, coupled with the prevalence of diabetic gastroparesis itself, are projected to fuel expansion within the market for its treatment. A surge in the volume of surgical interventions is expected to be a key driver for the diabetic gastroparesis treatment market moving ahead. Surgery encompasses a medical discipline focused on addressing diseases, injuries, or health conditions via operative techniques. Post-surgical gastroparesis in diabetic individuals can stem from various procedures, including Nissen fundoplication, gastrectomy, gastric bypass, pancreatectomy, vagotomy, and cholecystectomy, often due to damage to the vagus nerve which regulates food passage through the digestive system. For example, data from June 2024 by the American Society of Plastic Surgeons revealed that minimally invasive procedures saw a 7 percent increase in 2023, surpassing the growth rate of traditional surgical procedures by 2 percent, thereby underscoring the increasing trend in surgical interventions that consequently propels the diabetic gastroparesis treatment market.
Diabetic Gastroparesis Treatment Market Segment Performance And Strategic Opportunities
The diabetic gastroparesis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery
2) By Route Of Administration: Oral, Injectables
3) By Indication: Compensated Gastroparesis, Gastric Failure
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants
2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage
Diabetic Gastroparesis Treatment Market Innovation Trends: Which Developments Are Transforming The Industry?
Navigating the diabetic gastroparesis treatment landscape, key players are introducing sophisticated techniques like small bowel intubation to elevate both diagnostic precision and therapeutic outcomes, and in the United States, Avenacy, a pharmaceutical firm, took a significant step in September 2024 with the introduction of Metoclopramide Injection (USP), an injectable formulation targeting various conditions, prominently including the alleviation of diabetic gastroparesis symptoms, this solution aids in preventing chemotherapy and surgical-induced nausea and vomiting and further assists in small bowel intubation when standard approaches struggle to advance a tube past the pyloric sphincter, it also serves to accelerate gastric emptying and promote barium movement for radiological examinations.
Diabetic Gastroparesis Treatment Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the diabetic gastroparesis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC
Access The Complete Diabetic Gastroparesis Treatment Market Report:
Diabetic Gastroparesis Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the diabetic gastroparesis treatment market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
